TY - JOUR
T1 - Do Parkinson disease subject and caregiver-reported Epworth sleepiness scale reponses correlate?
AU - Shprecher, David R.
AU - Adler, Charles H.
AU - Zhang, Nan
AU - Shill, Holly A.
AU - Belden, Christine M.
AU - Driver-Dunckley, Erika
AU - Mehta, Shyamal H.
AU - Davis, Kathryn J.
AU - Sue, Lucia I.
AU - Zamrini, Edward
AU - Beach, Thomas G.
N1 - Funding Information:
This study was funded by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson’s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer’s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium), the Michael J. Fox Foundation for Parkinson’s Research , the Arizona Alzheimer’s Consortium and Mayo Clinic Foundation .
Funding Information:
CHA has received research funding from the Michael J. Fox Foundation, NIH, US Department of Defense, and the Arizona Biomedical Research Foundation, and has received consulting fees from Acadia, Acorda, Cynapsus, Jazz, Lundbeck, Merz, Minerva, Neurocrine, and Sunovion
Funding Information:
This study was funded by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium), the Michael J. Fox Foundation for Parkinson's Research, the Arizona Alzheimer's Consortium and Mayo Clinic Foundation.
Funding Information:
HS: received research support from Cynapsus/Sunovion, Axovant, Impax, US World Meds, Michael J. Fox Foundation and the NIH
Funding Information:
EZ: receives research support from Eli Lilly, Biogen, Pfizer, Merk, and NIH
Publisher Copyright:
© 2020
PY - 2020/5
Y1 - 2020/5
N2 - Objective: Subjective excessive daytime sleepiness, commonly measured with the Epworth Sleepiness Scale (ESS), is associated with cognitive impairment in Parkinson disease (PD). Significant correlation between subject and informant responses has been reported in neurologically healthy individuals. We sought to assess this correlation in patients with PD. Patients and Methods: 854 individuals in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) had subject as well as informant-completed ESS completed within one year of a movement disorder exam and cognitive assessment. Correlations were evaluated using Spearman's rank correlation coefficients. Results: Overall, 397/854(46.5 %) were female with mean age of 77.5 (SD 8.3). 572 (67 %) were cognitively normal (CogNL), 135 (15.8 %) had mild cognitive impairment (MCI) and 147 (17.2 %) dementia. Spearman R correlations (all with p < 0.001) between subject and informant ESS responses were 0.73 overall, 0.67 for the CogNL group, 0.79 for the MCI group, 0.79 for those with dementia. Of 175 with clinically probable PD, 115 (65.7 %) were CogNL, 38 had MCI, and 22 (12.6 %) dementia. For subjects with PD correlations (all with p < 0.001) were 0.65 for PD-CogNL, 0.83 for PD-MCI, and 0.70 for those with PD-dementia. Conclusion: These significant correlations between subject and informant-completed ESS can be useful in guiding clinical trials designed to assess efficacy of potential treatments for excessive daytime sleepiness for the general population and for patients with PD, even those having cognitive impairment.
AB - Objective: Subjective excessive daytime sleepiness, commonly measured with the Epworth Sleepiness Scale (ESS), is associated with cognitive impairment in Parkinson disease (PD). Significant correlation between subject and informant responses has been reported in neurologically healthy individuals. We sought to assess this correlation in patients with PD. Patients and Methods: 854 individuals in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND) had subject as well as informant-completed ESS completed within one year of a movement disorder exam and cognitive assessment. Correlations were evaluated using Spearman's rank correlation coefficients. Results: Overall, 397/854(46.5 %) were female with mean age of 77.5 (SD 8.3). 572 (67 %) were cognitively normal (CogNL), 135 (15.8 %) had mild cognitive impairment (MCI) and 147 (17.2 %) dementia. Spearman R correlations (all with p < 0.001) between subject and informant ESS responses were 0.73 overall, 0.67 for the CogNL group, 0.79 for the MCI group, 0.79 for those with dementia. Of 175 with clinically probable PD, 115 (65.7 %) were CogNL, 38 had MCI, and 22 (12.6 %) dementia. For subjects with PD correlations (all with p < 0.001) were 0.65 for PD-CogNL, 0.83 for PD-MCI, and 0.70 for those with PD-dementia. Conclusion: These significant correlations between subject and informant-completed ESS can be useful in guiding clinical trials designed to assess efficacy of potential treatments for excessive daytime sleepiness for the general population and for patients with PD, even those having cognitive impairment.
KW - Cognitive impairment
KW - Dementia
KW - Epworth sleepiness scale
KW - Excessive daytime sleepiness
KW - Mild cognitive impairment
KW - Parkinson disease
UR - http://www.scopus.com/inward/record.url?scp=85079190205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079190205&partnerID=8YFLogxK
U2 - 10.1016/j.clineuro.2020.105728
DO - 10.1016/j.clineuro.2020.105728
M3 - Article
C2 - 32058206
AN - SCOPUS:85079190205
SN - 0303-8467
VL - 192
JO - Clinical Neurology and Neurosurgery
JF - Clinical Neurology and Neurosurgery
M1 - 105728
ER -